TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Description: Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and urine sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study: NCT05639504

Intervention type: DIAGNOSTIC_TEST
Intervention: IMX-BVN-4 and IMX-SEV-4
Description: Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection

Intervention type: DIAGNOSTIC_TEST
Intervention: IMX-BVN-4 and IMX-SEV-4
Description: Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection

Intervention type: DIAGNOSTIC_TEST
Intervention: IMX-BVN-4 and IMX-SEV-4
Description: Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
Study: NCT06446271

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma biomarker levels
Description: This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma biomarker levels
Description: This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.
Study: NCT05469412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad®
Description: Use of Technology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
Study: NCT06130397

Intervention type: OTHER
Intervention: Cases reading
Description: The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1.

Intervention type: OTHER
Intervention: Ground truthing
Description: Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
Study: NCT05738447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV mRNA vaccine
Description: With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
Study: NCT06146413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double trigger
Description: GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: hCG ( 10000 IU) is administered 36 h before ovum pick-up
Study: NCT06471608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory management
Description: * Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days).
Study: NCT06143787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: 7 days Oral rinsing following tooth extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 7 days Oral rinsing following tooth extraction
Study: NCT04886362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Treatment with Ivermectin in the first 7 days from symptoms onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo in the first 7 days from symptoms onset.
Study: NCT05672589

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Relaxed Rotational Thromboelastometry
Description: Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Coagulation Tests
Description: Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
Study: NCT05343091

Intervention type: DEVICE
Intervention: cardiac ultrasound
Description: Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
Study: NCT05087121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)
Description: The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Inspire HR Wrist Worn Device (NCT04176926)
Description: The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926
Study: NCT06169956

Intervention type: DRUG
Intervention: Neoadjuvant nivolumab in combination with platinum-based chemotherapy
Description: Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
Study: NCT04255966

Intervention type: DEVICE
Intervention: Plasmafit® Revision Structan®
Description: Plasmafit® Revision Structan® Hip Endoprosthesis Cup
Study: NCT05369689

Intervention type: OTHER
Intervention: No interventions
Description: As this is a prognosis evaluation study, there are no interventions.
Study: NCT05133414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective left subclavian ansae stimulation
Description: Percutaneous, transarterial approach for target stimulation
Study: NCT05061602

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
Study: NCT05285202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding with linkage to preventive therapy (ACF/TPT)
Description: ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding with linkage to preventive therapy (ACF/TPT)
Description: ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
Study: NCT05393362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program (CR)
Description: Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
Study: NCT05744882

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: coronectony
Description: root canal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronectony
Description: root canal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment
Description: root canal treatment
Study: NCT06119906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper-Spectral Endoscopy
Description: We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
Study: NCT05433402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChlorproMAZINE 50 MG
Description: The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
Study: NCT05192980

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention NA
Description: Additional blood sampling (not mandatory)
Study: NCT05643482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Pressurization at 2.0 ATA with 100% oxygen

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo gas
Description: Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
Study: NCT05380986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with apatinib mesylate
Description: Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
Study: NCT05555602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-air cooling
Description: Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
Study: NCT06272695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volagidemab
Description: Administered by SC injection once weekly for 6 weeks
Study: NCT06061250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia
Description: To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
Study: NCT05290428

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation testing
Description: All cervical cytology samples will be tested for PAX1 and JAM3 methylation

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation testing
Description: All cervical cytology samples will be tested for PAX1 and JAM3 methylation
Study: NCT05982808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CLIF correction
Description: CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional correction strategy
Description: conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
Study: NCT05640388

Intervention type: OTHER
Intervention: RV3278A - ET0943 cosmetic product
Description: RV3278A - ET0943 study product is applied twice a day on the face during the whole study.

Intervention type: OTHER
Intervention: RV4632A - RY1845 cosmetic product
Description: RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
Study: NCT04924023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kaleidoscope application
Description: The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
Study: NCT06480253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet Continuous Positive Airway Pressure
Description: Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oronasal Mask Continuous Positive Airway Pressure
Description: Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
Study: NCT04731142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Huma
Description: Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video group consultations
Description: Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KNOW Diabetes
Description: Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Normal primary care service provided to matched control group.
Study: NCT04673877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic IV Vancomycin
Description: 1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bier Block
Description: After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
Study: NCT05442073

Intervention type: OTHER
Intervention: PEEP adjustment
Description: adjusting PEEP about 3-5cmH2O (increase or decrease)

Intervention type: OTHER
Intervention: PEEP adjustment
Description: adjusting PEEP about 3-5cmH2O (increase or decrease)
Study: NCT06187597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.